Market Overview

UPDATE: Jefferies Raises PT on AbbVie on Attractive Valuation

Share:
Related
Benzinga's M&A Chatter for Thursday April 28, 2016
Why Medivation Will Likely Reject Sanofi's $52.50/Share Buyout Offer
AbbVie (ABBV) Richard A. Gonzalez on Q1 2016 Results - Earnings Call Transcript (Seeking Alpha)

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on AbbVie (NYSE: ABBV), and raised the price target from $45.00 to $50.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

AbbVie closed on Tuesday at $42.55.

Latest Ratings for ABBV

DateFirmActionFromTo
Apr 2016Societe GeneraleInitiates Coverage onSell
Mar 2016Deutsche BankInitiates Coverage onHold
Mar 2016Goldman SachsDowngradesConviction BuyBuy

View More Analyst Ratings for ABBV
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (ABBV)

View Comments and Join the Discussion!